GPIIb-IIIa antagonists cost effective in acute coronary syndromes

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.499, 2006-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GPIIb-IIIa antagonists: upstream vs deferred use in acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1576, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Update on GPIIb/IIIa antagonists

By Hanson Julien   de Leval Xavier   Kolh Philippe   Supuran Claudiu   Pirotte Bernard   Dogné Jean-Michel  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1173-1188

Informa Healthcare

Access to resources Recommend Favorite

GP IIb/IIIa receptor antagonists beneficial in acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Cost-Effective Pharmacological Prevention of Acute Coronary Syndromes

By Monaco C.   Cianflone D.   Summaria F.   Maseri A.   Crea F.  

Pharmacological Research, Vol. 37, Iss. 6, 1998-06 ,pp. : 469-475

Academic Press

Access to resources Recommend Favorite

GPIIb/IIIa antagonists: the good, the bad and the not too ugly

By  

Inpharma, Vol. 1, Iss. 1616, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite